HOUSTON--(BUSINESS WIRE)--We are pleased to announce we are launching a line of supplements under our SomaceuticalsTM common identity to be marketed on our upcoming website to be named soma-ceuticals.com. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
Nutraceuticals lead off with StemStrengthTM, an all-natural stimulant for accelerated muscle and tissue development and RockOnTM, a potent libido complex tonic for male and female usage, containing popular ingredients for sexual health.
Cosmeceuticals include three products:
Rapid Wrinkle Reducer: a skin-smoothing serum gentle enough for everyday use. Instant results from plant extracts help reduce the appearance of fine lines and wrinkles and help to combat the appearance of aging skin.
Powerful Peptide Eye Serum: helps to reduce the appearance of eye bags, dark circles, and puffy eyes by relieving the accumulation of fluids and increasing the firmness around your eyes.
Collagen Anti-Aging Crème: nourishes and protects skin while encouraging skin cell renewal. It supports elastin and collagen production, which promotes skin moisture, elasticity, and thickness. It also has a healing effect on troubled or damaged skin areas.
Our lead pharmaceutical drug candidate is LiprostinTM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD). LiprostinTM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaceuticalsTM common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.